{"entity":{"id":"nct06580301","kind":"trial","name":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia","aka":[],"tldr":"A phase 1/2 trial of YK012 in acute lymphoblastic leukaemia, run by Excyte Biopharma Ltd, now recruiting.","summary":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT06580301 by Excyte Biopharma Ltd, with 46 participants planned, started 2024-09-25 and due to reach its primary completion in 2026-12-31. Interventions recorded: YK012.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06580301","url":"https://clinicaltrials.gov/study/NCT06580301"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06580301","phase":"1/2","setting":"An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YK012 in Participants With B-cell Acute Lymphoblastic Leukemia","sponsor":"Excyte Biopharma Ltd","enrolled":46,"outcomes":[]},"route":"/trials/nct06580301/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}]}}